Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 6, 1195 (2000)
doi:10.1038/81253
Merger signals shift in xenotransplantation research
Karen Birmingham1
- London
Xenotransplantation research in the United Kingdom is facing its second major setback this year. Following the August announcement that the Roslin Institute in Edinburgh is to cease work on its transgenic pig line amid concerns that pig viruses can infect human cells, the Swedish pharmaceutical company Novartis, has indicated its intention to close its Cambridge-based subsidiary, Imutran, by 31 December and merge its xeno research with the American company BioTransplant.
To read this story in full you will need to login or make a payment (see right).
